Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial

Fig. 2

Analysis of change from baseline in DAS28-CRP score. Change from baseline in DAS28-CRP score by visit for the a per-protocol set [p < 0.05 are shown by asterisk; week 12, p = 0.022] and b full analysis set [p < 0.05 are shown by asterisk; week 6, p = 0.026; week 10, p = 0.031; week 12, p = 0.015]. DAS28-CRP 28-joint Disease Activity Score, C-reactive protein version

Back to article page
\